SAN DIEGO, December 10, 2018– Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of PF708 for the treatment of osteoporosis. The…Original Article
You may also like
Orexo Submits New Drug Application to FDA for OX124, a...
FDA Accepts Defender Pharmaceuticals’ New Drug...
Abeona Therapeutics Submits Biologics License...
Alpha Cognition Announces Submission of New Drug...
Basilea Announces FDA Acceptance of New Drug...
FDA Issues Complete Response Letter for PDP-716 NDA...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.